Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 3Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

Cisplatin 10apatinib 5Surgical Procedures, Operative 4Radiotherapy 4Paclitaxel 4Hyperthermic Intraperitoneal Chemotherapy 4Hydralazine 4Gemcitabine 4Carboplatin 4Valproic Acid 3Neoadjuvant Therapy 3Drug Therapy 3Bevacizumab 3taxane 2pembrolizumab 2cetrorelix 2Radiotherapy, Intensity-Modulated 2Probiotics 2Population Groups 2Poly(ADP-ribose) Polymerase Inhibitors 2Metformin 2Laparoscopy 2Indocyanine Green 2Etoposide 2Curcumin 2CP protocol 2Brachytherapy 2spartalizumab 1piperine 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Immune Checkpoint Inhibitors × Gynecologic × Clear all
NCT06455072 2024-06-12

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Fujian Cancer Hospital

Phase 2 Recruiting
37 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡